NCT05695378View on ClinicalTrials.gov

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

PHASE2TerminatedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

August 19, 2024

Study Completion Date

August 19, 2024

Conditions
Multiple System Atrophy
Interventions
DRUG

KM-819

Subjects will receive KM-819 400 mg orally daily.

DRUG

Placebo

Subjects will receive Placebo orally daily.

Trial Locations (1)

13497

CHA Bundang Medical Center, CHA University, Seongnam-si

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Kainos Medicine Inc.

INDUSTRY